{"name":"Sylentis, S.A.","slug":"sylentis-s-a","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"SYL1001 ophthalmic solution","genericName":"SYL1001 ophthalmic solution","slug":"syl1001-ophthalmic-solution","indication":"Open-angle glaucoma or ocular hypertension","status":"phase_3"}]},{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Tivanisiran sodium ophthalmic solution","genericName":"Tivanisiran sodium ophthalmic solution","slug":"tivanisiran-sodium-ophthalmic-solution","indication":"Treatment of glaucoma","status":"phase_3"}]}],"pipeline":[{"name":"SYL1001 ophthalmic solution","genericName":"SYL1001 ophthalmic solution","slug":"syl1001-ophthalmic-solution","phase":"phase_3","mechanism":"SYL1001 is a small interfering RNA (siRNA) that silences the production of transforming growth factor-beta 2 (TGF-β2) to reduce intraocular pressure in glaucoma.","indications":["Open-angle glaucoma or ocular hypertension"],"catalyst":""},{"name":"Tivanisiran sodium ophthalmic solution","genericName":"Tivanisiran sodium ophthalmic solution","slug":"tivanisiran-sodium-ophthalmic-solution","phase":"phase_3","mechanism":"Tivanisiran sodium ophthalmic solution is an antisense oligonucleotide that targets the SOD1 gene to reduce the production of superoxide dismutase 1 protein.","indications":["Treatment of glaucoma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxNUTlueFcxMloxdHhmMklNRmVicU9oc1hZMkY1dElEeUNUeWJTdmV2YzJycktUNG1STmthZ1FOLXBweTM4WTZCZVF4TXc3VHVXS01rdUhfMXVUZmp4N3VBQUR5RkI2M2Q3b1pGaGNzeG5OZDF1YmdHWFZVQkkyMS1HTV9zMG96WEluMk12MU5XaEVWWHhhZXpmZ19Fd2pSelNuN0FoVXozMERsVHd0YnJVdlYyb1d1LTNJU1NQdWItM3hxZ3RlZ01mcw?oc=5","date":"2025-01-28","type":"pipeline","source":"prnewswire.com","summary":"Dry Eye Disease Market to Observe Stupendous Growth by 2034 | DelveInsight - prnewswire.com","headline":"Dry Eye Disease Market to Observe Stupendous Growth by 2034 | DelveInsight","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}